Stock BPMC BLUEPRINT MEDICINES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:01 01/05/2024 BST 		5-day change 1st Jan Change
94.98 USD +3.99% Intraday chart for Blueprint Medicines Corporation +2.95% +2.97%
04-25 Transcript : Blueprint Medicines Corporation - Special Call
03-22 Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing MT

Business Summary

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Number of employees: 655

Sales per Business

USD in Million2022Weight2023Weight Delta
Precision Therapies
100.0 %
204 100.0 % 249 100.0 % +22.22%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
91.1 %
190 93.3 % 227 91.1 % +19.38%
Rest of World
8.9 %
14 6.7 % 22 8.9 % +61.52%

Managers

Managers TitleAgeSince
Kathryn Haviland CEO
 Chief Executive Officer 48 04/01/16
Alexis Borisy FOU
 Founder 52 30/09/08
Michael Landsittel DFI
 Director of Finance/CFO 52 31/08/14
Jeffrey Albers CHM
 Chairman 52 23/07/14
Janet Loesberg CTO
 Chief Tech/Sci/R&D Officer 61 29/02/20
Becker Hewes CTO
 Chief Tech/Sci/R&D Officer 58 30/04/20
Percy Carter CTO
 Chief Tech/Sci/R&D Officer 53 18/05/21
Christina Rossi COO
 Chief Operating Officer 48 28/10/18
Christopher Murray CTO
 Chief Tech/Sci/R&D Officer 61 09/10/17
Tracey McCain CMP
 Compliance Officer 56 05/09/16

Members of the board

Members of the board TitleAgeSince
Lynn Seely BRD
 Director/Board Member 65 13/04/16
Alexis Borisy FOU
 Founder 52 30/09/08
Lonnel Coats BRD
 Director/Board Member 58 03/02/16
Nicholas B. Lydon FOU
 Founder 67 30/09/08
Mark Goldberg BRD
 Director/Board Member 69 24/06/15
Daniella Beckman BRD
 Director/Board Member 45 07/12/21
Jeffrey Albers CHM
 Chairman 52 23/07/14
Kathryn Haviland CEO
 Chief Executive Officer 48 04/01/16
Habib Dable BRD
 Director/Board Member 54 22/06/22
John Tsai BRD
 Director/Board Member 57 05/01/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,814,862 62,276,683 ( 99.14 %) 0 99.14 %

Shareholders

NameEquities%Valuation
T. Rowe Price Associates, Inc. (Investment Management)
10.21 %
6,250,823 10.21 % 593 M $
Vanguard Fiduciary Trust Co.
9.987 %
6,114,970 9.987 % 580 M $
BlackRock Advisors LLC
9.741 %
5,964,833 9.741 % 566 M $
T. Rowe Price International Ltd.
8.866 %
5,428,955 8.866 % 515 M $
Fidelity Management & Research Co. LLC
7.101 %
4,348,311 7.101 % 412 M $
Wellington Management Co. LLP
6.984 %
4,276,333 6.984 % 406 M $
Rock Springs Capital Management LP
4.706 %
2,881,567 4.706 % 273 M $
STATE STREET CORPORATION
3.959 %
2,424,200 3.959 % 230 M $
Pictet Asset Management Holding SA
2.864 %
1,753,547 2.864 % 166 M $
William Blair Investment Management LLC
2.822 %
1,727,845 2.822 % 164 M $

Company contact information

Blueprint Medicines Corp.

45 Sidney Street

02139, Cambridge

+617 374 7580

http://www.blueprintmedicines.com
address Blueprint Medicines Corporation(BPMC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Blueprint Medicines Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
94.98 USD
Average target price
98.06 USD
Spread / Average Target
+3.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BLUEPRINT MEDICINES CORPORATION Stock Blueprint Medicines Corporation
+2.97% 5.74B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BPMC Stock
  4. Company Blueprint Medicines Corporation